Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic
  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Olema Oncology to Present at Upcoming Investor Conferences in November

SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company will present at the following investor conferences in November:

  • Presentation at the Credit Suisse 31st Annual Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, CA, on Wednesday, November 9, at 9:10 a.m. Pacific Time (12:10 p.m. Eastern Time)
  • Fireside chat at the Jefferies London Healthcare Conference at The Waldorf Hilton in London, UK, on Wednesday, November 16, at 11:30 a.m. GMT (6:30 a.m. Eastern Time)
  • Virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, at 2:40 p.m. Eastern Time

Live webcasts of the presentations and any accompanying presentation materials will be available under the Investors & Media section of Olema’s website (www.olema.com) and will be archived for at least 30 days.

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 2 clinical trial, and in combination with CDK 4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted FDA Fast Track designation. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.

IR Contact:
Shane Kovacs, COO and CFO
ir@olema.com

Media Contact:
Ignacio Guerrero-Ros, Ph.D., Russo Partners
646-942-5604
ignacio.guerrero-ros@russopartnersllc.com


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.